Effect of <i>in vivo</i> treatment with an anti-CD69 monoclonal antibody (mAb) on DSS-induced colitis.

<p>(A) Wild-type (WT) BALB/c mice were treated with an anti-CD69 mAb or control hamster IgG on day 0. The survival of each group during DSS-induced colitis was recorded daily (n = 5 per group). (B, C) Changes in the disease activity index (B) and body weight (%) (C) over the course of DSS treatment in WT mice treated with the anti-CD69 mAb or control hamster IgG. The data are presented as the means (SD) (n = 5 per group). *p<0.01. **p<0.05. (D) Histological sections. Colons were taken on day 8 from control and DSS-exposed WT mice treated with the anti-CD69 mAb or control hamster IgG. Sections were fixed and stained with hematoxylin and eosin (original magnification 40×). Three independent experiments were performed with similar results.